These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28289706)

  • 1. Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy.
    Kaifer KA; Villalón E; Osman EY; Glascock JJ; Arnold LL; Cornelison DDW; Lorson CL
    JCI Insight; 2017 Mar; 2(5):e89970. PubMed ID: 28289706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse.
    McGovern VL; Massoni-Laporte A; Wang X; Le TT; Le HT; Beattie CE; Rich MM; Burghes AH
    PLoS One; 2015; 10(7):e0132364. PubMed ID: 26134627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.
    Hosseinibarkooie S; Peters M; Torres-Benito L; Rastetter RH; Hupperich K; Hoffmann A; Mendoza-Ferreira N; Kaczmarek A; Janzen E; Milbradt J; Lamkemeyer T; Rigo F; Bennett CF; Guschlbauer C; Büschges A; Hammerschmidt M; Riessland M; Kye MJ; Clemen CS; Wirth B
    Am J Hum Genet; 2016 Sep; 99(3):647-665. PubMed ID: 27499521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
    Strathmann EA; Peters M; Hosseinibarkooie S; Rigo FW; Bennett CF; Zaworski PG; Chen KS; Nothnagel M; Wirth B
    PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.
    Villalón E; Kline RA; Smith CE; Lorson ZC; Osman EY; O'Day S; Murray LM; Lorson CL
    Hum Mol Genet; 2019 Nov; 28(22):3742-3754. PubMed ID: 31363739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved therapeutic approach for spinal muscular atrophy via ubiquitination-resistant survival motor neuron variant.
    Rhee J; Kang JS; Jo YW; Yoo K; Kim YL; Hann SH; Kim YE; Kim H; Kim JH; Kong YY
    J Cachexia Sarcopenia Muscle; 2024 Aug; 15(4):1404-1417. PubMed ID: 38650097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality.
    Ackermann B; Kröber S; Torres-Benito L; Borgmann A; Peters M; Hosseini Barkooie SM; Tejero R; Jakubik M; Schreml J; Milbradt J; Wunderlich TF; Riessland M; Tabares L; Wirth B
    Hum Mol Genet; 2013 Apr; 22(7):1328-47. PubMed ID: 23263861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice.
    Besse A; Astord S; Marais T; Roda M; Giroux B; Lejeune FX; Relaix F; Smeriglio P; Barkats M; Biferi MG
    Mol Ther; 2020 Aug; 28(8):1887-1901. PubMed ID: 32470325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
    Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
    Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
    Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.
    Riessland M; Kaczmarek A; Schneider S; Swoboda KJ; Löhr H; Bradler C; Grysko V; Dimitriadi M; Hosseinibarkooie S; Torres-Benito L; Peters M; Upadhyay A; Biglari N; Kröber S; Hölker I; Garbes L; Gilissen C; Hoischen A; Nürnberg G; Nürnberg P; Walter M; Rigo F; Bennett CF; Kye MJ; Hart AC; Hammerschmidt M; Kloppenburg P; Wirth B
    Am J Hum Genet; 2017 Feb; 100(2):297-315. PubMed ID: 28132687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy.
    Walsh MB; Janzen E; Wingrove E; Hosseinibarkooie S; Muela NR; Davidow L; Dimitriadi M; Norabuena EM; Rubin LL; Wirth B; Hart AC
    BMC Biol; 2020 Sep; 18(1):127. PubMed ID: 32938453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
    Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
    J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.